Today: 22 May 2026
Oklo stock jumps nearly 11% on new Buy coverage as nuclear trade wakes up again
29 January 2026
1 min read

Oklo stock jumps nearly 11% on new Buy coverage as nuclear trade wakes up again

New York, Jan 28, 2026, 21:21 EST — The market has closed.

  • Oklo ended the day 10.8% higher at $94.39, having reached $95.25 at one point.
  • Texas Capital Securities initiated coverage, setting a Buy rating and a price target of $138.
  • Traders are balancing renewed analyst optimism with the lengthy timeline required for new nuclear projects.

Oklo Inc. shares surged Wednesday following Texas Capital Securities’ initiation of coverage with a Buy rating, reigniting interest in the nuclear start-up. The stock finished 10.8% higher at $94.39.

This shift is significant as investors search for “always-on” power options to support data centers, putting nuclear back in the spotlight. Oklo remains in the build-and-permit phase and is driven more by story and funding risks than by immediate revenue prospects.

Washington is ramping up its focus on small reactors, which are promoted as faster to construct than conventional plants. This month, the U.S. Department of Energy handed out significant grants for small modular reactor projects, underscoring how policy shifts can rapidly sway sentiment in this sector.

Oklo has pushed to tie its narrative to big-load demand. Just earlier this month, the company teamed up with Meta, unveiling a deal to back 1.2 gigawatts of nuclear power in southern Ohio.

Texas Capital set a $138 price target, dubbing Oklo “the best investment vehicle for those bullish on advanced nuclear solutions.” The firm highlighted Oklo’s Aurora design — a sodium-cooled fast reactor that uses liquid sodium instead of water as a coolant. But the note also warned about the uneven setup: Oklo isn’t profitable yet, and its shares can swing widely. The stock’s moves hinge more on permitting, customer funding, and build milestones than on quarterly earnings. Investing.com

Still, even the bulls are betting on a long timeline. New reactors require licenses, supply chains, and flawless construction—any delay could push back schedules and increase the risk of further dilution throughout the sector.

Traders will be watching the next session closely to see if Wednesday’s surge in volume and new coverage lead to sustained gains or if the stock slips back into a choppy trading range.

The initial challenge arrives Thursday morning (Jan. 29), as investors decide if the fresh $138 target will attract more buyers following the recent close-to-close surge.

Stock Market Today

  • Q1 Earnings Review: Azenta Falls; West Pharmaceutical Leads Drug Development Services Stocks
    May 21, 2026, 9:31 PM EDT. Drug development inputs and services stocks, essential for pharmaceutical research and manufacturing, reported mixed Q1 results. Azenta (NASDAQ:AZTA), specializing in biological sample management, posted disappointing results with $144.8 million revenue, missing estimates and the weakest among peers, causing its share price to drop 23.4% to $17.65. Conversely, West Pharmaceutical Services (NYSE:WST), maker of specialized packaging and delivery devices, delivered a strong quarter with $844.9 million revenue, beating estimates by 8.4%. Overall, the sector's revenues beat consensus by 1.6%, despite an average 2.5% share price decline post-earnings. Tailwinds include growth in biologics and gene therapies, while headwinds feature pricing pressure and regulatory risks.

Latest articles

OpenAI Shares Hype Returns, Still No Ticker in Sight

OpenAI Shares Hype Returns, Still No Ticker in Sight

22 May 2026
OpenAI is preparing to confidentially file for a U.S. IPO, aiming to go public as early as September, sources told Reuters. The move follows a court win against Elon Musk, removing a key legal obstacle. Private-market share prices for OpenAI ranged from $658.94 to $732.38 this month, but no official public price exists. Ordinary investors still cannot buy OpenAI stock on public exchanges.
Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

22 May 2026
Estée Lauder and Spain’s Puig ended merger talks that would have created a $40 billion beauty group. Estée Lauder shares rose about 10% in after-hours trading, closing the regular session at $78.91. The company said it will focus on its turnaround plan and continue reviewing possible acquisitions or divestitures.
WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

22 May 2026
WhiteFiber shares jumped 22.2% to $29.55 after announcing a five-year AI compute contract worth over $160 million for a Paris-region deployment using NVIDIA GPU systems. Google Finance showed the stock rising further after hours. The project is backed by planned financing and 12 months of customer prepayments, but funding and execution remain pending. Service is expected to start in July, subject to equipment delivery and acceptance.
Danaher (DHR) stock slides nearly 5% after earnings beat as 2026 outlook lands “in line”
Previous Story

Danaher (DHR) stock slides nearly 5% after earnings beat as 2026 outlook lands “in line”

Goldman Sachs stock ticks up after leadership shake-up — what Wall Street watches next
Next Story

Goldman Sachs stock ticks up after leadership shake-up — what Wall Street watches next

Go toTop